Wrocław-based biotech company BIOTTS is developing several drug-delivery programmes based on its proprietary MTC-Y technology, including insulin administered through the skin and both transdermal and oral forms of semaglutide. The most advanced project, developed with Bioton, is designed to deliver insulin without injections. The company is also preparing for a potential Warsaw Stock Exchange debut in 2027.
BIOTTS is building its pipeline around a platform intended to transport active pharmaceutical substances through the skin. The technology is aimed at compounds that are currently injected or have limited bioavailability when taken orally.
Needle-free insulin is the most advanced programme
The company’s lead project, MTC-INS, is a transdermal insulin formulation developed in cooperation with Bioton. BIOTTS says preclinical studies in large animals produced bioavailability of 21.8% in the first 24 hours and 55.1% after 72 hours.
The company also says its data indicate that one patch could potentially replace three injections. These results remain preclinical, however, and do not establish how the treatment will perform in people. Human trials will be needed to confirm both efficacy and safety.
BIOTTS is currently conducting studies under Good Laboratory Practice standards and plans a pilot study of transdermal insulin in Australia. Stability testing of the formulation has so far reached 270 days and is expected to continue for up to two years.
Semaglutide is being developed in two forms
The company is also working on semaglutide, the active ingredient widely used in the treatment of type 2 diabetes and obesity. BIOTTS is pursuing two separate delivery routes: transdermal and oral.
For the oral programme, the company says its preclinical research produced bioavailability roughly ten times higher than that of an oral formulation currently available on the market. As with the insulin programme, the result still needs to be confirmed in further studies, including clinical trials in humans.
Higher bioavailability could potentially reduce the amount of active substance required for a therapeutic effect, which could have both technological and cost implications if the results are reproduced later in development.
A third project targets a rare metabolic disorder
BIOTTS is also developing a programme related to Smith-Lemli-Opitz syndrome, a rare metabolic disease associated with impaired cholesterol synthesis. The project focuses on delivering cholesterol to the central nervous system and is currently at an earlier stage than the insulin programme.
Further studies in large animals are planned following the company’s initial preclinical work.
Six patents and around PLN 50 million of financing
Intellectual property is a central part of the company’s strategy. BIOTTS says it holds six patents and has broader protection for its platform and selected drug-delivery solutions across a number of markets.
The company says it has secured around PLN 50 million in financing from investors and public programmes. Some funding for the insulin project has also come from European initiatives, including EIC Horizon.
BIOTTS operates its own laboratory and R&D team while also working with external partners. Bioton is the most prominent partner in the transdermal insulin programme, while the company has also reported cooperation or earlier projects involving Kaneka and the Polish Academy of Sciences.
The business model is based on multiple assets, not one drug
Rather than depending on a single medicine, BIOTTS aims to create a portfolio of projects built on the same delivery platform. Individual programmes could later be commercialised through licensing, partnerships or transactions with larger pharmaceutical companies.
The value of those projects will depend heavily on the next stages of development. Positive preclinical results are important, but the decisive milestone will be whether the technology produces comparable results in people.
Warsaw Stock Exchange debut targeted for 2027
BIOTTS says it is preparing for a possible listing on the Warsaw Stock Exchange in 2027. Funds raised from the public market would be used to support further clinical work and expand the number of projects using the MTC-Y platform.
The planned IPO would place the company among a relatively small group of Polish biotechnology businesses attempting to finance late-stage research through the public market. Before then, the most important value-creation events will come from the transition of its lead programmes from preclinical testing into human studies.
Source: BIOTTS company information and data cited in the original ManagerPlus analysis.
